AA
CGON icon

ALPS Advisors’s CG Oncology CGON Stock Holding History

ALPS Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.34M Buy
89,218
+20,481
+30% +$1.34M 0.03% 241
2026
Q1 		$4.65M Buy
68,737
+2,699
+4% +$153K 0.02% 261
2025
Q4 		$2.74M Buy
66,038
+28,524
+76% +$1.18M 0.02% 341
2025
Q3 		$1.51M Sell
37,514
-3,555
-9% -$103K 0.01% 430
2025
Q2 		$1.07M Sell
41,069
-15,330
-27% -$369K 0.01% 487
2025
Q1 		$1.38M Buy
56,399
+1,709
+3% +$48.1K 0.01% 407
2024
Q4 		$1.57M Buy
54,690
+831
+2% +$28.4K 0.01% 382
2024
Q3 		$2.03M Buy
53,859
+1,878
+4% +$65.8K 0.01% 359
2024
Q2 		$1.64M Buy
+51,981
New +$1.8M 0.01% 369

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's CGON Position: Q2 2026 in Review

ALPS Advisors increased its CG Oncology (CGON) stake by 30% in Q2 2026, buying an estimated $1.34M and bringing the position to 89,218 shares worth $6.34M. The position accounts for 0.03% of the portfolio, ranked #241.

ALPS Advisors first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • ALPS Advisors held 89,218 shares of CG Oncology worth $6.34M as of Q2 2026.
  • ALPS Advisors bought 20,481 CG Oncology shares in Q2 2026, an estimated $1.34M.
  • CG Oncology made up 0.03% of ALPS Advisors's portfolio in Q2 2026, its #241 holding.
  • ALPS Advisors first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.